Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/195747
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rischin, Danny | - |
dc.contributor.author | Harrington, Kevin J. | - |
dc.contributor.author | Greil, Richard | - |
dc.contributor.author | Soulières, Denis | - |
dc.contributor.author | Tahara, Makoto | - |
dc.contributor.author | Castro, Gilberto de | - |
dc.contributor.author | Psyrri, Amanda | - |
dc.contributor.author | Braña, Irene | - |
dc.contributor.author | Neupane, Prakash | - |
dc.contributor.author | Bratland, Åse | - |
dc.contributor.author | Fuereder, Thorsten | - |
dc.contributor.author | Hughes, Brett G.M. | - |
dc.contributor.author | Mesía Nin, Ricard | - |
dc.contributor.author | Ngamphaiboon, Nuttapong | - |
dc.contributor.author | Rordorf, Tamara | - |
dc.contributor.author | Ishak, Wan Zamaniah Wan | - |
dc.contributor.author | Hong, Ruey-Long | - |
dc.contributor.author | González Mendoza, René | - |
dc.contributor.author | Jia, Liyi | - |
dc.contributor.author | Chirovsky, Diana | - |
dc.contributor.author | Norquist, Josephine | - |
dc.contributor.author | Jin, Fan | - |
dc.contributor.author | Burtness, Barbara | - |
dc.date.accessioned | 2023-03-21T18:11:11Z | - |
dc.date.available | 2023-03-21T18:11:11Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 1368-8375 | - |
dc.identifier.uri | http://hdl.handle.net/2445/195747 | - |
dc.description.abstract | Objectives: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031). Materials and methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L). Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing. Results: Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups. At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, -3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, -3.46 to 4.26). Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL. TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores. Conclusions: Pembrolizumab monotherapy and pembrolizumab-chemotherapy extended OS while maintaining HRQoL, further supporting first-line use for R/M HNSCC. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Ltd | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1016/j.oraloncology.2022.105815 | - |
dc.relation.ispartof | Oral Oncology, 2022, vol. 128 | - |
dc.relation.uri | https://doi.org/10.1016/j.oraloncology.2022.105815 | - |
dc.rights | cc-by-nc-nd (c) Elsevier Ltd, 2022 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.classification | Malalties cròniques | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.other | Monoclonal antibodies | - |
dc.subject.other | Chemotherapy | - |
dc.subject.other | Chronic diseases | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Head cancer | - |
dc.title | Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 732735 | - |
dc.date.updated | 2023-03-21T18:11:11Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
732735.pdf | 2.84 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License